Gilead Sciences (GILD) Preferred Stock Liabilities (2012 - 2015)
Gilead Sciences (GILD) posted Preferred Stock Liabilities of $2.0 million for Q4 2015, down 50.0% quarter-over-quarter from $4.0 million in Q3 2015, and down 86.67% year-on-year from $15.0 million in Q4 2014.
Gilead Sciences (GILD) Preferred Stock Liabilities (2012 - 2015) Analysis & Trends
Gilead Sciences (GILD) has reported Preferred Stock Liabilities for 4 consecutive years, with $2.0 million the latest figure, recorded in Q4 2015.
- Preferred Stock Liabilities for Q4 2015 came in at $2.0 million, down 86.67% year-over-year; the trailing twelve-month figure through Dec 2015 was $2.0 million (down 86.67% YoY), and the FY2015 annual result was $2.0 million, down 86.67% from the prior year.
- Preferred Stock Liabilities was $2.0 million for Q4 2015 at Gilead Sciences, down from $4.0 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $64.0 million in Q4 2013 and troughed at $2.0 million in Q4 2015.
- Average Preferred Stock Liabilities over 4 years is $21.9 million, with a median of $13.0 million recorded in 2014.
- Year-over-year, Preferred Stock Liabilities jumped 795.48% in 2013 and tumbled 86.67% in 2015.
- Over 4 years, Preferred Stock Liabilities stood at $7.1 million in 2012, then jumped by 795.48% to $64.0 million in 2013, then plunged by 76.56% to $15.0 million in 2014, then sank by 86.67% to $2.0 million in 2015.
- Per Business Quant data, the three most recent Preferred Stock Liabilities figures were $2.0 million in Q4 2015, $4.0 million in Q3 2015, and $7.0 million in Q2 2015.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 2.00 Mn |
| Sep 30, 2015 | 4.00 Mn |
| Jun 30, 2015 | 7.00 Mn |
| Mar 31, 2015 | 11.00 Mn |
| Dec 31, 2014 | 15.00 Mn |
| Sep 30, 2014 | 27.38 Mn |
| Jun 30, 2014 | 35.88 Mn |
| Mar 31, 2014 | 45.77 Mn |
| Dec 31, 2013 | 64.00 Mn |
| Dec 31, 2012 | 7.15 Mn |